situations; exactly which medicines are regarded as essential remains a national responsibility." 3 In this paper, we review the list's history, evolution, application by countries, controversies, and future challenges. 4 
History
The 1975 World Health Assembly 5 asked WHO to assist member states in selecting and procuring essential medicines, assuring good quality and reasonable cost (panel 1). 2, 4, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The first list of 205 items (186 medicines) was published 2 years later. 2 At the 1978 Alma Ata conference, provision of essential medicines was identified as one of eight key components of primary health care. 6 The 1985 Nairobi conference resulted in the development of WHO's revised drug strategy, in which the model list was recognised as important mainly for public sectors; the emphasis was moved beyond selection of drugs to their procurement, distribution, rational use, and quality assurance. 9 In 1991, membership of the WHO Expert Committee on the Use of Essential Drugs was balanced by including "professionals in essential drugs programmes in developing countries" 4 and by providing comparative cost information. 4 During this period, many countries and NGOs adopted the essential medicines approach, 10 and the UN emergency health kit included 55 of the list medicines.
When the 1999 expert committee met to revise the model list, they expressed concern at the lack of evidence provided to justify revisions and asked that "a summary of the appropriate evidence be presented for review".
The first WHO essential drugs list, published in 1977, was described as a peaceful revolution in international public health. The list helped to establish the principle that some medicines were more useful than others and that essential medicines were often inaccessible to many populations. Since then, the essential medicines list (EML) has increased in size; defining an essential medicine has moved from an experience to an evidence-based process, including criteria such as publichealth relevance, efficacy, safety, and cost-effectiveness. High priced medicines such as antiretrovirals are now included. Differences exist between the WHO model EML and national EMLs since countries face varying challenges relating to costs, drug effectiveness, morbidity patterns, and rationality of prescribing. Ensuring equitable access to and rational use of essential medicines has been promoted through WHO's revised drug strategy. This approach has required an engagement by WHO on issues such as the effect of international trade agreements on access to essential medicines and research and development to ensure availability of new essential medicines.
Search strategy
We did comprehensive literature searches using Medline and EMBASE. Emphasis was placed on articles published from 1975-2002 containing information on the implementation, use, effect, and relevance of essential drug lists in developing countries.
published in May, 2001, 14 an evidence-based transparent process for revising the list was proposed. This document was generally well received by member states, with the exception of the USA, which attacked every aspect of the list in a detailed memorandum. 15 Areas of dispute included the applicability of the list to developed countries and cost considerations. After detailed rebuttals, the final revised procedure was adopted by the WHO Executive Board in January, 2002. 16 In April that year, a meeting of the expert committee was held under the new procedures, and several patented antiretrovirals were added to the list. 17 
Evolution of the EML
The structure of the WHO model EML has remained largely unchanged since first published; medicines are divided into two categories: core, defined as efficacious, safe, and cost-effective medicines for priority conditions (selected on the basis of current and estimated future public-health relevance and potential for safe and costeffective treatment); and complementary, defined as "medicines for priority diseases which are efficacious, safe and cost-effective but not necessarily affordable, or for which specialized health care facilities or services may be needed" 19 . Some medicines have been added and deleted many times. Amodiaquine was on the original list, deleted in 1979 because "of its similarity to choloroquine", 20 re-added in 1982 as a suspension on the complementary list, and removed by name in 1987 "since the square symbol [which indicates that there are many possible medicines in a therapeutic class that can be used to treat a given condition] before chloroquine adequately covers use of this drug". 21 In 1995, the expert committee clarified that the square box next to chloroquine "is retained solely to accommodate hydroxychloroquine" (panel 3). 22 
Relevance of the EML to countries
A cross-sectional analysis of 17 national EMLs, shows that 68% contain fewer than 300 medicines (range 108-389), compared with 309 on the WHO EML in 1999 (table 2) . The amodiaquine case illustrates the apparent disconnection between selection decisions made by WHO expert committees and those made by WHO experts creating treatment guidelines. Amodiaquine was deleted from treatment guidelines by the malaria expert committee in 1990 because of safety concerns and for lack of apparent advantage over chloroquine. 23 In 1993, however, amodiaquine use was recommended in cases in which benefits outweighed risks (WHO 19th Malaria Expert Committee, 1993) and eventually reinstated in WHO treatment guidelines in 1996 24 on the basis of results of a systematic review. Several countries have followed WHO treatment guideline recommendations, which has spurred many organisations to request that amodiaquine be re-added to the WHO model EML. 
South Africa and essential medicines
South Africa's experience in many ways mirrors global challenges. In 1994, the country emerged from decades of isolation and a political system geared to meet the needs of an affluent elite. Among the first new health strategies was the 1996 national drug policy, which was firmly committed to the use of an essential medicines list.
26 Although a limited list had been used in the public sector from the mid-1980s, this list had expanded to include some 2600 items. In the immediate political pre-transition period, the Department of Pharmacology at the University of Cape Town put forward a list of around 250 active medicines (350 formulations) organised in four levels of care ranging from self-medication to medical specialist.
The South African list was developed by a committee under intense time pressure, much of it from the political leadership. The first edition of standard treatment guidelines and medicines (about 160) for primary health care was released within 2 months of publication of the national drug policy. Critics immediately claimed the committee lacked input from primary-care providers and was pharmacist-dominated, and that the list was overly focused on disease rather than on syndromes or presenting problems. 27 After a review process, membership of the committee was expanded. Although the South African committees still mainly drew on experience and expert opinion, they sought first to develop standard treatment guidelines, from which necessary medicine lists were extracted. At the end of 1998, a three-volume set of these lists was released, aimed at primary health care and paediatric and adult hospital care.
Although the lists were widely distributed, implementation was described as patchy and considerable challenges remained, 28 including the apparent dislocation between the EDL committee and the structures responsible for design of programmes and training material. The committees were, in effect, dissolved once the books were published; maintenance of the lists was therefore neglected, and guidelines produced by national vertical programmes increasingly deviated from the selection made by the EDL committee. A prominent example was the guideline for postexposure prophylaxis for rape victims, which in addition to including antiretrovirals suggested the use of azithromycin; 29 the drug is not available in state facilities and no tender for its procurement has been issued. HIV has been an issue of great concern in the EDL process. Although the 1998 list mentions an ideal treatment approach for HIV and opportunistic infections, it includes a warning that the medicines are "very costly and cannot be provided on a mass scale by the public health services . . . it may only be provided on a limited and selective basis or for academic and research purposes only".
A new committee is being appointed to revise the list, including people from major programmes such as maternal and child health, non-communicable diseases, AIDS, tuberculosis, and mental health. Nominations have also been sought from provincial pharmacy and therapeutics committees. There is also commitment to an evidencebased approach. Furthermore, the new lists will address allocating prescriber levels, neglected in the 1998 lists, partly because of time pressures.
However, country-level EMLs face challenges that the WHO model list does not-they must result in changes in the field, save costs, increase rationality of prescribing, and improve patients' outcome. Although some baseline data were collected, follow-up studies are too small to provide meaningful conclusions. To align procurement processes with the list is also difficult; around 1600 different medicines are still procured by the South African public sector. The increasing use of evidence-based formularies in the private sector is, however, promising. 30 
Revising the Eritrean national list of drugs
The first Eritrean national list of drugs was defined in 1993 and contained 305 medicines, the second (in 1996) contained 315, and the third (2001) contained 325. All three editions underwent exhaustive review involving most health professionals in the country. The WHO model list served as the basis for the first edition, which was produced by about 30 health professionals. For the second and third revisions, comments were reviewed at national workshops attended by more than 100 people, including health professionals and officials of the Ministry of Health, professional associations, governmental and international organisations, and international consultants. Immediately after its publication, the list gained almost universal acceptance. The formation of hospital drug and therapeutic committees and compilation of individual hospital lists of medicines into a national list assisted this evidence-based approach and is recommended for future reviews (Information provided by Embaye Andom, Ministry of Health, Eritrea).
Implementation and advocacy: the role of NGOs
The first director of the WHO Action Programme on Essential Drugs described the essential medicines concept as a peaceful revolution in international public health. Others characterised the EML as "a brilliant symbolic strategy on the part of WHO for mobilising opinion and resources". 31 However, pharmaceutical companies have consistently opposed the concept. In 1987, the International Federation of the Pharmaceutical Manufacturers Associations (IFPMA) called the medical and economic arguments for the EML fallacious and claimed that adopting it "could result in sub-optimal medical care and might reduce health standards". 32 The pharmaceutical industry was concerned that the EML would become a global concept applicable to public and private sectors in developing and developed countries, and were especially opposed to attempts by developed countries to introduce limited medicines lists. In 1982, a spokesman of the US pharmaceutical manufacturers organisation said "The industry feels strongly that any efforts by the WHO and national governments to implement this action program should not interfere with existing private sector operations". The Italian drug industry put it more crudely in response to the Italian senate's attempts to introduce an EML, stating "If they want to turn Italy into a third world country, this is the way to go about it". 33 The drug industry's view that EMLs are only for the public sector of the poorest nations has not changed much in the past 25 years. The current IFPMA paper about essential medicines repeats that view and says that policies extending restrictive drug policies to industrialised countries pose a serious threat to the delivery of effective health care and to investment in drug research. 32 NGOs have advocated for political support for WHO's work on essential medicines and for implementation of essential medicines policies at the national level (panel 4). Furthermore, they have a substantial role in the provision of health care in resource-poor settings, and have used the EML for the selection and procurement of medicines. The importance of this approach is perhaps best illustrated by the chaos and risks posed by inappropriate drug donations; in Lithuania 11 women went blind as a result of a veterinary drug, donated by a European NGO, being given mistakenly for gynaecological problems.
34
By the mid-1980s, international agencies including NGOs such as Médecins Sans Frontières and Oxfam and professional bodies such as the British Medical Association and the International Pharmaceutical Federation (FIP) had adopted essential medicine policies. 7 The International Federation of Red Cross and Red Crescent Societies has a comprehensive essential medicines policy 35 and Médecins Sans Frontières has an essential medicines guide designed to address practical field needs. 36 In 1998, a group of NGOs published a guide to encourage NGOs to adopt such policies for their own operations or as a condition for funding other groups. 37 In 1981, around 50 NGOs met in Geneva to form Health Action International (HAI) whose aims include "the safe, rational and economic use of pharmaceuticals world-wide . . . and full implementation of the WHO Action programme on essential drugs." HAI has been a strong advocate for EMLS at the national and international level.
However, advocacy for the availability of essential medicines and removal of non-essential and dangerous medicines from the market was not sufficient to ensure their rational use. In 1982, HAI put forward a draft code of practice that addressed the need for international norms on promotion, distribution, trade, and technology in the pharmaceutical sector. Though an international code on the pharmaceutical sector was never devised, the World Health Assembly adopted a comprehensive pharmaceutical policy within the WHO Medicines Strategy in 1986. 38 The strategy has the aim of ensuring equitable access to essential medicines of acceptable quality, promoting rational use of medicines, and implementing national medicine policies. In 2001, the WHO Medicines Strategy was expanded to include a mandate for WHO to work on trade-related issues affecting the availability of medicines. 39 
EML and intellectual property
The AIDS crisis has highlighted the grave inequity in access to essential medicines and has drawn attention to the potential consequences of WTO agreements on the availability of medicines. Most AIDS medicines are fairly new and are produced in what is effectively a monopoly. Once the TRIPS agreement is fully implemented (by 2016 for least-developed countries) the cost of all new medicines worldwide will largely depend on price setting by the patent holder.
In 1996, an Assembly resolution requested WHO to "report on the impact of the work of the World Trade Organization with respect to national drug policies and essential medicines and make recommendations for collaboration between WTO and WHO, as appropriate". 40 In 1998, WHO published the first guide containing recommendations to member states for implementing TRIPS while restricting the negative effects of increased patent protection on drug availability. 41 At that time, WHO's involvement in trade issues was highly controversial. The emphasis on public health needs versus trade was seen as a threat in the industrialised world. In 1998, the Directorate General for Trade of the European Commission concluded, referring to "considerable concern among the pharmaceutical industry", "that no priority should be given to health over intellectual property considerations". 42 However, subsequent resolutions of the World Health Assembly have strengthened WHO's mandate with respect to trade. In 2001, two resolutions addressed the need to strengthen policies to increase the availability of generic medicines and assess the effect of TRIPS on access to medicines, local manufacturing capacity, and development of new medicines. 43, 44 At the 1999 third ministerial conference of WTO in Seattle, several developing countries proposed adding medicines on the WHO list to the exceptions to what could be patented allowed under TRIPS article 27.3(b) . 45 47 this proposal would have greatly limited the scope of compulsory licensing. The Seattle conference collapsed and no conclusion was reached.
2001 saw the WTO Doha Declaration on TRIPS and Public Health, which acknowledged the right of countries to take measures to protect public health: ". . . while reiterating our commitments to the TRIPS Agreement, we affirm that the Agreement can and should be interpreted and implemented in a manner supportive of WTO Members' right to protect public health and, in particular, to promote access to medicines for all." 48 For this statement to be of practical use, the issue of the right of countries to produce generic medicines for export must be adequately addressed. 49 
Future perspectives
The 25-year-old essential medicines concept serves as the basis for the WHO medicines strategy in operation today. 50 It has become a global concept used by governments and health-care providers worldwide.
The development of an evidence-based list within WHO will be mirrored in countries attempting to implement the essential medicines concept, which poses major challenges. Evidence used by WHO to add or remove a drug might provide some basis for change in country-level decisionmaking, but in some cases local trials might also be necessary. WHO's web-based Medicines Library will provide information, 51 prices, 52 and evidence for decisions, to assist national committees (figure). Training committee members in the use of evidence-based medicine resources might also be necessary.
Another area that national committees could find challenging is cost-effectiveness analysis. International measures of effectiveness might be locally applicable and local costs can be incorporated, but local clinical trials might be needed to measure effectiveness and international prices might have to be used for medicines which are not yet available in the country. Countries might benefit from international assistance with these issues, as occurred in Eritrea.
Changes are underway within WHO to ensure that future EMLs are evidence based. The Essential Drugs and Medicines Policy Department has defined the new processes, and for the 2002 revision of the list it provided technical assistance to specific departments in developing submissions to the expert committee. It also supports the identification of medicines that are no longer essential and could be removed. However, the implications for the clinical or disease control departments in WHO are profound. In the past, every department developed treatment guidelines as an independent activity. Now, they will all need to provide evidence that supports inclusion of the medicines in their guidelines on the model list. Given that the EU and US delegations to the TRIPS Council considered WHO's recent advice 54 on how to ensure production and export of generic medicines as being outside WHO's mandate, WHO will have to insist on its duty to advocate for health in future trade debates. This role includes addressing the issue of the lack of pharmaceutical research and development for health needs in developing countries. Only 1% of medicines developed in the past 25 years have been aimed at these diseases, despite the substantial burden that they cause. 55 The pharmaceutical industry has engaged in several public-private partnerships, but they are largely still focused on diseases where there is an economic incentive (ie, AIDS, malaria, and tuberculosis) and it is too early to say whether they will be successful. Where will the new essential medicines for meeting needs specific to developing countries come from?
Although many people in the world still lack effective access to essential medicines, the work done by WHO and its partners has done much to bridge this gap. The original insight that a restricted list of well chosen medicines could meet the needs of most of the world remains as valid now as it did in 1977. However, the fundamental human right to access to these medicines remains a challenge and will require further action at the national and international levels. 
